Institution Directory

Clinical trials at UT Southwestern Medical Center

Sites in Dallas, TX

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1263

Shown on this page

Current sort

Live official records

Conditions: Generalised Lipodystrophy, Partial Lipodystrophy
Interventions: Metreleptin; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2031
U.S. locations: 16
States / cities: Birmingham, Alabama • Duarte, California • Atlanta, Georgia + 11 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: DWN12088, Placebo; Drug
Lead sponsor: Daewoong Pharmaceutical Co. LTD.; Industry
Eligibility: 40 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 20
States / cities: Mesa, Arizona • Phoenix, Arizona • San Francisco, California + 14 more

Conditions: Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions: Biospecimen Collection, Drug Withdrawn, Quality-of-Life Assessment, Questionnaire Administration, Tyrosine Kinase Inhibitor; Procedure · Other · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 25 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 157
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 123 more

Conditions: Bladder Cancer
Interventions: Pembrolizumab, Enfortumab vedotin (EV), RC + PLND, Gemcitabine, Cisplatin; Biological · Procedure · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 808 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 22
States / cities: Phoenix, Arizona • Fullerton, California • Los Angeles, California + 19 more

Conditions: Lung Cancer
Interventions: lobectomy, segmentectomy or wedge resection; Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 373
States / cities: Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 245 more

Conditions: Medulloblastoma
Interventions: Cisplatin, Cyclophosphamide, Laboratory Biomarker Analysis, Lomustine, Magnetic Resonance Imaging, Radiation Therapy, Vincristine, Vincristine Sulfate; Drug · Other · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 173
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 134 more

Conditions: Obesity and Obesity-related Medical Conditions, Spinal Cord Injury, Chronic
Interventions: Telehealth with dietician; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Advanced Melanoma
Interventions: Vusolimogene Oderparepvec, Nivolumab, Nivolumab + Relatlimab, Pembrolizumab, Single-agent chemotherapy; Biological · Drug
Lead sponsor: Replimune, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 50
States / cities: Gilbert, Arizona • La Jolla, California • Los Angeles, California + 42 more

Conditions: Treatment Resistant Depression, Undergoing Deep Brain Stimulation (DBS) Surgery
Interventions: Abbott Laboratories Infinity™ implantable deep brain stimulation system; Device
Lead sponsor: Nader Pouratian; Other
Eligibility: 21 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Alcohol-associated Hepatitis
Interventions: IL-22, Prednisone, Acamprosate, Prednisone placebo, IL-22 (F-652) Placebo, Motivational Interviewing (MI), Motivational Enhancement Therapy (MET), Usual Care; Drug · Behavioral
Lead sponsor: Samer Gawrieh; Other
Eligibility: 18 Years to 70 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: Indianapolis, Indiana • Louisville, Kentucky • Rochester, Minnesota + 3 more

Conditions: Lichen Sclerosus of Vulva
Interventions: Nemolizumab 30 mg; Biological
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Cytarabine, Daunorubicin, Electrocardiography, Pemigatinib; Procedure · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Portland, Oregon • Dallas, Texas

About this UT Southwestern Medical Center institution page

What this page lists: ClinicalTrials.gov records that list UT Southwestern Medical Center in Dallas, TX as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at UT Southwestern Medical Center

Filter and sort this campus

Live official records

MEASuRE: Metreleptin Effectiveness And Safety Registry

Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

UTSW NORC Pilot Spinal Cord Injury Dietary Program

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

Tractography Guided Subcallosal Cingulate Deep Brain Stimulation for Treatment Resistant Depression

Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial

Nemolizumab for LS

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

About this UT Southwestern Medical Center institution page